Trial Finds Bezuclastinib Demonstrates Improvement With Regard To Symptoms, Biomarkers For Mast Cell Burden In Patients With Non-Advanced Systemic Mastocytosis

Cancer Network (12/16, Dobkowski) reports data “from the phase 2 Summit trial...showed that, in patients with non-advanced systemic mastocytosis, a 100 mg dose of bezuclastinib was judged to be safe and demonstrated significant improvement with regard to symptoms and biomarkers for mast cell burden.” The investigators “noted that this abstract reported on patients treated with both bezuclastinib formulations in parts 1a or 1b of the trial, which had similar pharmacokinetic exposures.” This research “focuses on the 24-week outcomes of patients receiving the selected 100-mg dose of bezuclastinib and participating in the open-label extension.” The findings were presented at the ASH Annual Meeting & Exposition.